Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adenovirus + herpes simplex virus thymidine kinase
- Development stage
- Unknown
- Lead developer
- Candel Therapeutics
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intratumoral, Intracerebral, Intrapleural
01
Overview
Adenovirus + herpes simplex virus thymidine kinase is a gene therapy approach that uses a replication-deficient adenoviral vector to deliver the herpes simplex virus type 1 thymidine kinase (HSV-tk) gene into tumor cells. Once inside the cell, HSV-tk phosphorylates the prodrug ganciclovir (or similar nucleoside analogs), converting it into toxic metabolites that induce cell death. This system is designed as a targeted cytotoxic immunotherapy for cancer treatment—primarily high-grade gliomas and other localized malignancies—by selectively killing transduced tumor cells and potentially stimulating an anti-tumor immune response. The therapy has been evaluated in clinical trials for recurrent glioblastoma and high-grade glioma, showing improved progression-free survival and overall survival compared to conventional treatments[1][2][4]. It has also been studied preclinically in mesothelioma and lung cancer models[3].
- Other names
- adenovirus-mediated herpes simplex virus thymidine kinaseAdv-tkADV/HSV-tk
02
Targets
DNA polymerase familyHSV-TK (Herpes simplex virus type 1 thymidine kinase (HSV1-TK))
Beyond the preview
Go deeper on adenovirus + herpes simplex virus thymidine kinase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adenovirus + herpes simplex virus thymidine kinase.